Citius Pharmaceuticals Inc(CTXR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 22 at 7:53 PM ET (Korea 9/23 08:53)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -2.11 | Insider Own | 1.8% | Shs Outstand | 27.4M | Perf Week | 6.8% |
| Market Cap | 0.02B | Forward P/E | - | EPS next Y | 29.06% | Insider Trans | - | Shs Float | 27.0M | Perf Month | -0.33% |
| Enterprise Value | 0.02B | PEG | - | EPS next Q | -0.41 | Inst Own | 4.95% | Short Float | 20.89% | Perf Quarter | 6.82% |
| Income | -0.05B | P/S | 2.31 | EPS this Y | 39.94% | Inst Trans | -2.14% | Short Ratio | 10.54 | Perf Half Y | -20.37% |
| Sales | 0.01B | P/B | 0.25 | EPS next 5Y | 41.69% | ROA | -34.29% | Short Interest | 5.63M | Perf YTD | -23.01% |
| Book/sh | 2.43 | P/C | 0.97 | EPS past 3/5Y | 16.24% 21.29% | ROE | -70.29% | 52W High | -72.68% ($2.19) | Perf Year | -48.43% |
| Cash/sh | 0.62 | P/FCF | - | Sales past 3/5Y | - | ROIC | -62.86% | 52W Low | 27.63% ($0.47) | Perf 3Y | -96.57% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 57.48% | Gross Margin | 19.97% | Volatility(W/M) | 4.59% 5.81% | Perf 5Y | -98.88% |
| Dividend TTM | - | EV/Sales | 2.24 | Sales Y/Y TTM | - | Oper. Margin | -863.92% | ATR (14) | 0.04 | Perf 10Y | -99.75% |
| Dividend Ex-Date | - | Quick Ratio | 0.4 | EPS Q/Q | 57.59% | Profit Margin | -651.27% | RSI (14) | 50.92 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.84 | Sales Q/Q | - | SMA20 | 1.95% ($0.59) | Beta | 1 | Target Price | $4 |
| Payout | - | Debt/Eq | 0.11 | Earnings | 2026/8/14 | SMA50 | 0.53% ($0.6) | Rel Volume | 0.4 | Prev Close | $0.58 |
| Employees | 23 | LT Debt/Eq | 0.11 | EPS/Sales Surpr. | 5.56% -72.64% | SMA200 | -17.61% ($0.73) | Avg Volume(3M) | 0.53M | Price | $0.6 |
| IPO | 2014/10/2 | Option/Short | Yes/Yes | Trades | 543 | Volume | 215,265 | Change | 3.76% |
Company
CTXR is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💊 A small pharmaceutical company currently selling LYMPHIR, a novel lymphoma drug, in the early commercialization stage. Its subsidiary, Citius Oncology (CTOR), handles the oncology pipeline, while the parent company, CTXR, holds late-stage clinical assets such as Mino-Lok® (a catheter infection prevention agent) and Halo-Lido (a hemorrhoid treatment). It is a diversified, mixed-stage small-cap biopharma spanning clinical development and commercialization.
Over the past 1 year, on the lower side
73% below its 1-year high.
CTXR has weak earning power
Review management risk carefully before investing
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +39.9% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -96.6% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Short interest is a burden
Institutions hold 5.0%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
VXF 0.00%It ranks #4 in the industry
Based on market cap of $16M.
CTXR $16M PER -
VRTX $131B PER 30.0
REGN $83B PER 19.9
MRNA $73B PER -
FAQ
What kind of company is CTXR?
CTXR belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CTXR?
The market cap of CTXR is approximately $16M, ranking 5,345 within its sector.
What is the 52-week high and low for CTXR?
CTXR has recorded a 52-week high of $2.19 and a low of $0.47.
